Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.2%

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 2,568,740 shares, a growth of 38.2% from the December 15th total of 1,858,418 shares. Currently, 13.9% of the company’s stock are sold short. Based on an average daily trading volume, of 339,981 shares, the short-interest ratio is currently 7.6 days. Based on an average daily trading volume, of 339,981 shares, the short-interest ratio is currently 7.6 days. Currently, 13.9% of the company’s stock are sold short.

Institutional Investors Weigh In On Avalo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of Avalo Therapeutics by 2.5% during the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after buying an additional 2,648 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Avalo Therapeutics during the second quarter worth approximately $55,000. Velan Capital Investment Management LP boosted its holdings in shares of Avalo Therapeutics by 38.4% during the second quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after acquiring an additional 43,000 shares during the period. Nantahala Capital Management LLC boosted its holdings in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after acquiring an additional 95,000 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Avalo Therapeutics by 7,066.8% in the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock valued at $2,029,000 after purchasing an additional 400,898 shares during the last quarter. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $15.06 on Friday. The company’s 50-day moving average is $17.59 and its 200-day moving average is $13.06. The firm has a market capitalization of $278.76 million, a PE ratio of -2.81 and a beta of 0.84. Avalo Therapeutics has a fifty-two week low of $3.39 and a fifty-two week high of $20.72.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, analysts expect that Avalo Therapeutics will post -19.07 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently commented on AVTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Monday, September 29th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Avalo Therapeutics in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.71.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.